Analyst Price Targets — IRON
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 17, 2026 1:34 pm | — | Wedbush | $88.00 | $60.28 | TheFly | Disc Medicine price target lowered to $88 from $110 at Wedbush |
| February 17, 2026 1:21 pm | Kristen Kluska | Cantor Fitzgerald | $125.00 | $60.24 | TheFly | Disc Medicine price target lowered to $125 from $153 at Cantor Fitzgerald |
| February 17, 2026 1:14 pm | — | Morgan Stanley | $75.00 | $60.39 | TheFly | Disc Medicine price target lowered to $75 from $120 at Morgan Stanley |
| February 17, 2026 1:05 pm | — | Stifel Nicolaus | $110.00 | $61.43 | TheFly | Disc Medicine price target lowered to $110 from $125 at Stifel |
| February 17, 2026 12:56 pm | Evan Seigerman | BMO Capital | $100.00 | $61.48 | TheFly | Disc Medicine price target lowered to $100 from $120 at BMO Capital |
| January 8, 2026 12:40 pm | — | Morgan Stanley | $120.00 | $80.94 | TheFly | Disc Medicine price target raised to $120 from $115 at Morgan Stanley |
| December 8, 2025 1:20 pm | Martin Auster | Raymond James | $117.00 | $96.32 | StreetInsider | Disc Medicine (IRON) PT Raised to $117 at Raymond James |
| November 10, 2025 2:52 pm | — | Truist Financial | $114.00 | $82.77 | TheFly | Disc Medicine price target raised to $114 from $86 at Truist |
| October 17, 2025 1:04 pm | — | National Bank | $153.00 | $94.19 | TheFly | Disc Medicine price target raised to $153 from $132 at Cantor Fitzgerald |
| October 17, 2025 12:01 pm | — | Raymond James | $108.00 | $74.36 | TheFly | Disc Medicine price target raised to $108 from $89 at Raymond James |
Latest News for IRON
New York, New York--(Newsfile Corp. - March 4, 2026) - Levi & Korsinsky notifies investors that it has commenced an investigation into Disc Medicine, Inc. ("Disc Medicine, Inc.") (NASDAQ: IRON) concerning potential violations of the federal securities laws. On February 13, 2026, Disc disclosed that the FDA had issued a Complete Response Letter (CRL) for bitopertin, the company's lead therapeutic candidate targeting…
Jean Franchi sold 11,156 shares of common stock in open-market transactions for a total value of ~$720,000, with an average price around $64.51 per share on Feb. 17 and Feb. 18, 2026. The sale represented 13.52% of Franchi's direct holdings, reducing direct ownership from 82,499 to 71,343 shares.
NEW YORK, Feb. 26, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Disc Medicine, Inc. ("Disc" or the "Company") (NASDAQ: IRON). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.
WATERTOWN, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases, today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided a review of recent program and corporate…
Hedge fund BVF added 650,000 shares of Disc Medicine in the fourth quarter. The quarter-end position value rose by $51.62 million as a result.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IRON.
U.S. House Trading
No House trades found for IRON.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.